KR20230107228A - Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 - Google Patents

Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 Download PDF

Info

Publication number
KR20230107228A
KR20230107228A KR1020237015423A KR20237015423A KR20230107228A KR 20230107228 A KR20230107228 A KR 20230107228A KR 1020237015423 A KR1020237015423 A KR 1020237015423A KR 20237015423 A KR20237015423 A KR 20237015423A KR 20230107228 A KR20230107228 A KR 20230107228A
Authority
KR
South Korea
Prior art keywords
therapy
alkyl
administration
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015423A
Other languages
English (en)
Korean (ko)
Inventor
마키 곤도
Original Assignee
오노 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오노 야꾸힝 고교 가부시키가이샤 filed Critical 오노 야꾸힝 고교 가부시키가이샤
Publication of KR20230107228A publication Critical patent/KR20230107228A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237015423A 2020-11-13 2021-11-12 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 Pending KR20230107228A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JPJP-P-2020-189152 2020-11-13
JP2020189152 2020-11-13
JP2020211006 2020-12-21
JPJP-P-2020-211006 2020-12-21
JP2021006828 2021-01-20
JPJP-P-2021-006828 2021-01-20
PCT/JP2021/041650 WO2022102731A1 (ja) 2020-11-13 2021-11-12 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Publications (1)

Publication Number Publication Date
KR20230107228A true KR20230107228A (ko) 2023-07-14

Family

ID=81602339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015423A Pending KR20230107228A (ko) 2020-11-13 2021-11-12 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Country Status (6)

Country Link
US (1) US20230390303A1 (https=)
EP (1) EP4245301A4 (https=)
JP (2) JP7816164B2 (https=)
KR (1) KR20230107228A (https=)
TW (1) TW202228674A (https=)
WO (1) WO2022102731A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111347A1 (ja) 2015-01-09 2016-07-14 小野薬品工業株式会社 三環性スピロ化合物
WO2018008711A1 (ja) 2016-07-07 2018-01-11 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1258473A4 (en) 2000-02-22 2004-09-01 Ono Pharmaceutical Co BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT
EP1312601A4 (en) 2000-08-22 2005-09-21 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
CA2419722A1 (en) 2000-09-01 2003-02-21 Masaki Asada Benzoic acid derivatives and drugs containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CN1662551A (zh) 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
DE602004013938D1 (de) 2003-01-29 2008-07-03 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
KR20060130123A (ko) 2003-12-22 2006-12-18 아스텔라스세이야쿠 가부시키가이샤 프로스타글란딘 ｅ2 작용제 또는 길항제로서의 오르니틴유도체
JP4054369B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2006122403A1 (en) 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
US8969394B2 (en) 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
PE20131343A1 (es) 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
NZ609887A (en) 2010-09-29 2015-01-30 Nb Health Lab Co Ltd Antibody against human prostaglandin e2 receptor ep4
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
CA2860392C (en) 2011-12-21 2016-08-30 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013096496A2 (en) 2011-12-21 2013-06-27 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2862263C (en) 2011-12-27 2016-09-06 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2862266C (en) 2011-12-27 2016-10-04 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
CA2914997C (en) 2013-06-12 2021-07-20 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
ME02896B (me) 2013-12-17 2018-04-20 Lilly Co Eli Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
ME03398B (me) 2013-12-17 2020-01-20 Lilly Co Eli Spojevi dimetilbenzojeve kiseline
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
EP3099667B1 (en) 2014-01-27 2017-11-01 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016088903A1 (en) 2014-12-05 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
JP6837632B2 (ja) 2015-07-17 2021-03-03 凸版印刷株式会社 体液試料の単位量当たりのセルフリーｄｎａ量を健康状態の評価のための指標とする方法
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP6269888B1 (ja) * 2016-07-07 2018-01-31 小野薬品工業株式会社 医薬用途
WO2018195123A1 (en) 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
JP7211358B2 (ja) 2017-05-22 2023-01-24 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
CN108929281B (zh) 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
CN109836434B (zh) 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
US20230167504A1 (en) 2017-12-13 2023-06-01 Hiroshima University Method for aiding detection of pancreatic cancer
WO2019152982A1 (en) 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic compounds as ep4 antagonists
EP3759114A4 (en) 2018-03-02 2021-12-15 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBONIC ACIDS AND SALT THEREOF
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
KR20210040064A (ko) 2018-07-12 2021-04-12 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서의 (r)-4-(1-(1-(4-(트리플루오로메틸)벤질)피롤리딘-2-카복스아미드)사이클로프로필 벤조산
JP7491220B2 (ja) 2018-11-27 2024-05-28 小野薬品工業株式会社 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
US12240812B2 (en) 2019-01-22 2025-03-04 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
EP3693359A1 (en) 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111347A1 (ja) 2015-01-09 2016-07-14 小野薬品工業株式会社 三環性スピロ化合物
WO2018008711A1 (ja) 2016-07-07 2018-01-11 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: 저널 오브 리피드 메디에이터즈 앤드 셀 시그널링(Journal of Lipid Mediators and Cell Signalling), 제12권, 379-391 페이지, 1995년
비특허문헌 2: 파마콜로지컬 리뷰즈(Pharmacological Reviews), 제65권, 1010-1052 페이지, 7월, 2013년
비특허문헌 3: 제105회 미국암연구회의(American Association for Cancer Research(AACR)), 요지 번호: LB-265, 프레젠테이션 표제: ONO-AE3-208 inhibits myeloid derived suppressor cells and glioma growth, 프레젠테이션 일시: 2014년 4월 8일
비특허문헌 4: 페브스 레터즈(FEBS Letters), 제364권, 339-341 페이지, 1995년
비특허문헌 5: 캔서 사이언스(Cancer Science), 제105권, 1142-1151 페이지, 2014년
비특허문헌 6: 캔서 리서치(Cancer Research), 제70권, 1606-1615 페이지, 2010년
비특허문헌 7: 캔서 리서치(Cancer Research), 제62권, 28-32 페이지, 2002년

Also Published As

Publication number Publication date
TW202228674A (zh) 2022-08-01
US20230390303A1 (en) 2023-12-07
JPWO2022102731A1 (https=) 2022-05-19
JP7816164B2 (ja) 2026-02-18
EP4245301A4 (en) 2024-08-21
EP4245301A1 (en) 2023-09-20
JP2026067904A (ja) 2026-04-21
WO2022102731A1 (ja) 2022-05-19

Similar Documents

Publication Publication Date Title
JP6885390B2 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
JP7156287B2 (ja) Ａｘｌ阻害剤を有効成分として含むがん治療剤
KR102800132B1 (ko) Sting 작동 화합물
KR102473601B1 (ko) Ep4 길항약과 면역 체크 포인트 저해약을 포함하여 이루어진 조합
JP6698648B2 (ja) ユビキチン活性化酵素阻害物質及び化学療法剤の投与
US10335411B2 (en) Administration of ubiquitin-activating enzyme inhibitor and radiation
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
JPWO2017155018A1 (ja) Ｔｒｋ阻害剤抵抗性の癌治療剤
JPWO2018117177A1 (ja) Ｂｒｋ阻害化合物
JPWO2018216640A1 (ja) Ｅｐ４アンタゴニスト
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
JP7816164B2 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
WO2019049891A1 (ja) Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
RU2820817C2 (ru) Комбинированное лечение злокачественного новообразования с использованием сульфонамидного соединения и иммунорегулятора
RU2798265C2 (ru) Соединение, обладающее агонистической активностью в отношении sting
CA3247160A1 (en) CLASS OF QUINOLEIN COMPOUNDS, THEIR PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION AND THEIR USES
HK40002610A (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
NZ789384A (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241105

Comment text: Request for Examination of Application